Rubedo Life Sciences today announced the selection of the first-in-class development candidate RLS-1496 for the treatment of dermatological conditions using its ALEMBIC™ drug discovery platform at LSX World Conference 2023.
Rubedo Life Sciences today announced the selection of the first-in-class development candidate RLS-1496 for the treatment of dermatological conditions using its ALEMBIC™ drug discovery platform at LSX World Conference 2023.